More employers drop weight-management GLP-1 coverage at renewal
Withdrawals land mid-treatment, and interruption is the mechanism that undoes results.
Withdrawals land mid-treatment, and interruption is the mechanism that undoes results.
All-in monthly cost at 10 mg
Employer plans have continued to narrow or drop weight-management coverage at renewal. Diabetes indications are generally unaffected; the weight-management category is what gets cut.
Categorical exclusions cannot be appealed on medical necessity, because they are plan design rather than a coverage determination.
If coverage is ending, price the cash market before your last covered fill rather than after it.
What this changes for what you pay
Most developments in this category move one of three things: the price of the branded product, which programmes are operating, or what may lawfully be compounded. Very few change the prescription requirement, the pharmacy licensing framework or the clinical review behind a prescription.
The cheapest verified compounded route we track currently sits at $215 a month all-in at a 10 mg maintenance dose, about $2,580 for a first year. Where a development moves that figure, our tables move with it on the next build.
How to verify this yourself
Regulatory claims should be checked against the agency rather than against coverage of the agency. FDA publishes warning letters searchable by company name, a shortage database, and its compounding pages. Trial claims should be checked against the registry entry rather than a press release.
Every source behind this item is linked below, and where a story is still moving we say so rather than implying it is settled.
Open these rather than taking our word for it. Every one is a regulator, a trial registry, a label, an accreditor or the manufacturer.
Compare every programme on one screen
The matrix carries all-in price at every dose, fee structure, commitment terms, pharmacy disclosure and verification status for every programme we track.